Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008–20.

Article  CAS  PubMed  Google Scholar 

Oba A, Ho F, Bao OR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant treatment in pancreatic cancer. Front Oncol. 2020;10:245.

Article  PubMed  PubMed Central  Google Scholar 

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

Article  CAS  PubMed  Google Scholar 

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.

Article  Google Scholar 

Stoop TF, Theijse RT, Seelen LWF. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024;21(2):101–24.

Article  PubMed  Google Scholar 

Oba A, Del Chiaro M, Fujii T, et al. “Conversion surgery” for locally advanced pancreatic cancer: a position paper by the study group at the joint meeting of the international association of pancreatology (IAP) & Japan pancreas society (JPS) 2022. Pancreatology. 2023;23(6):712–20.

Article  PubMed  Google Scholar 

Oba A, Del Chiaro M, Satoi S, et al. New criteria of resectability for pancreatic cancer: a position paper by the Japanese society of hepato-biliary-pancreatic surgery (JSHBPS). J Hepatobiliary Pancreat Sci. 2022;29(7):725–31.

Article  PubMed  Google Scholar 

Brown ZJ, Heh V, Labiner HE, et al. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Br J Surg. 2022;110:34–42.

Article  PubMed  Google Scholar 

Eshmuminov D, Aminjonov B, Palm RF, et al. FOLFIRINOX or gemcitabine-based chemotherapy for borderline resectable and locally advanced pancreatic cancer: a multi-institutional, patient-level, meta-analysis and systematic review. Ann Surg Oncol. 2023;30(7):4417–28.

Article  PubMed  PubMed Central  Google Scholar 

Theijse RT, Stoop TF, Janssen QP, et al. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: a TAPS consortium study. Br J Surg. 2024;111(3):znae033.

Article  PubMed  PubMed Central  Google Scholar 

Rangelova E, Wefer A, Persson S, et al. Surgery improves survival after neoadjuvant therapy for borderline and locally advanced pancreatic cancer: a single institution experience. Ann Surg. 2021;273(3):579–86.

Article  PubMed  Google Scholar 

Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer. Ann Surg. 2021;273(2):341–9.

Article  PubMed  Google Scholar 

Hackert T, Sachsenmaier M, Hinz U, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264(3):457–63.

Article  PubMed  Google Scholar 

Maggino L, Malleo G, Marchegiani G, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154(10):932–42.

Article  PubMed  PubMed Central  Google Scholar 

Ushida Y, Inoue Y, Oba A, et al. Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gemcitabine plus nab-paclitaxel: a single-center retrospective study. Ann Surg Oncol. 2022;29(8):5038–50.

Article  PubMed  Google Scholar 

Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;70(2):340–7.

Article  Google Scholar 

Garnier J, Ewald J, Marchese U, et al. Borderline or locally advanced pancreatic adenocarcinoma: a single center experience on the FOLFIRINOX induction regimen. Eur J Surg Oncol. 2020;46(8):1510–5.

Article  PubMed  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–9.

Article  Google Scholar 

van Rijssen LB, Groot Koerkamp B, Zwart MJ, et al. Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch pancreatic cancer audit. HPB. 2017;19(10):919–26.

Article  PubMed  Google Scholar 

Walma MS, Brada LJ, Patuleia SIS, et al. Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: a multicenter prospective cohort. Eur J Surg Oncol. 2021;20:699–707.

Article  Google Scholar 

Dutch Pancreatic Cancer Group. DPCG-definities resectabiliteit pancreascarcinoom. Dutch Pancreatic Cancer Group; 2012.

Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 1.2022, NCCN clinical practice guidelines in oncology. National comprehensive cancer network. 11 Apr 2022. Available at: https://www.nccn.org/guidelines/guidlines-detail?category=1&id=1455. Accessed 11 Apr 2022.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

Article  CAS  PubMed  Google Scholar 

Soloff E, Al-Hawary M, Desser TS, Fishman EK, Minter RM, Zins M. Imaging assessment of pancreatic cancer resectability after neoadjuvant therapy: AJR expert panel narrative review. AJR Am J Roentgenol. 2022;218(4):570–81.

Article  PubMed  Google Scholar 

Stoop TF, Seelen LWF, van't Land FR, et al. PREOPANC4 implementation program for locally advanced pancreatic cancer (PREOPANC-4). 1 Sep 2022. Available at: https://clinicaltrials.gov/ct2/show/NCT05524090?term=PREOPANC4&draw=2&rank=1. Accessed 3 Sep 2022.

RStudio: Integrated development for R. RStudio, PBC, Boston. (2020).

Sperandei S. Understanding logistic regression analysis. Biochem Med. 2014;24(1):12–8.

Article  Google Scholar 

Seelen LWF, Doppenberg D, Stoop TF, et al. Minimum and optimal CA19-9 response after two months induction chemotherapy in patients with locally advanced pancreatic cancer: a nationwide multicenter study. Ann Surg. 2024;279(5):832–41. https://doi.org/10.1097/sla.0000000000006021.

Article  PubMed  Google Scholar 

Michelakos T, Pergolini I, Castillo CF, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2019;269(4):733–40.

Article  PubMed  Google Scholar 

Weniger M, Moir J, Damm M, et al. Respect: a multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Pancreatology. 2020;20(6):1131–8.

Article  CAS  PubMed  Google Scholar 

McIntyre CA, Cohen NA, Goldman DA, et al. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. J Surg Oncol. 2022;125(3):425–36.

Article  PubMed  Google Scholar 

Schneider M, Hackert T, Strobel O, Büchler MW. Technical advances in surgery for pancreatic cancer. Br J Surg. 2021;108(7):777–85.

Article  CAS  PubMed  Google Scholar 

Groot VP, Blair AB, Gemenetzis G, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Eur J Surg Oncol. 2019;45(9):1674–83.

Article  PubMed  Google Scholar 

Seelen LW, Van Oosten AF, Brada LJ, Groot VP, Daamen LA, Walma MS, Van Der Lek BF, Liem MS, Patijn GA, Stommel MW, Van Dam RM. Early recurrence after resection of locally advanced pancreatic cancer following induction therapy: an international multicenter study. Ann Surg. 2023;278(1):118–26.

Article  PubMed  Google Scholar 

Wu YHA, Oba A, Lin R, Watanabe S, Meguid C, Schulick RD, Del Chiaro M. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. J Gastrointest Oncol. 2021;12(5):2475–83.

Article  PubMed  PubMed Central  Google Scholar 

Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.

Article  PubMed  Google Scholar 

Ghidini M, Vuozzo M, Galassi B, et al. The role of positron emission tomography/computed tomography (PET/CT) for staging and disease response assessment in localized and locally advanced pancreatic cancer. Cancers. 2021;13(16):4155.